Is CBD a drug of abuse? Updates on TAR Appeal

The TAR suspends the decision on the classification of CBD as a drug of abuse

In the latest hearing at the Regional Administrative Court (TAR), held on April 16, 2024, the suspension of the ministerial decision regarding the classification of CBD as a drug of abuse has been confirmed until September. This update comes after an intense hearing, during which the key points of the controversy regarding the placement of CBD in Schedule B of medicines, qualifying it as a drug of abuse, were discussed.

Lawyers Lorenzo Simonetti and Claudio Miglio, representing Canapa Sativa Italia, participated in the hearing along with other companies. During the hearing, the defense of the Ministry of Health requested the postponement of the decision to September 24, 2024, pending the opinions of the Higher Health Council and the Higher Institute of Health.

However, defense lawyers criticized this request for postponement, emphasizing the lack of scientific basis supporting the classification of CBD as a drug of abuse. “The Ministry cannot issue an illegitimate decree and then attempt to retroactively legitimize the classification with new studies in the course of the process to repair the serious deficiencies it carries” – the lawyers argue, criticizing the Ministry’s attempt to retroactively legitimize the classification with new studies.

Legal Implications and Defense Strategies

The legal effort to assert CBD as a non-narcotic substance has been intensified through collaboration between various companies that led the initial challenge against the ministerial decree of August 7, 2023. This decree modified regulations on controlled substances, including the placement of CBD. This situation highlights the complexity of legal and regulatory issues related to substance categorization and the effect such decisions have on emerging industries and public opinion. The legal battle against the ministerial decree is crucial for the fate of the hemp industry in Italy and could set an important precedent for the regulation and perception of substances like CBD in the country.

The group of companies, under the guidance of Canapa Sativa Italia, has filed a series of targeted appeals to revoke the decree and to obtain a thorough and justified scientific review. Lawyers Miglio and Simonetti argue that CBD has never been considered a drug of abuse by any scientific source, reaffirming the need to base legislative decisions on concrete evidence.

Economic and Social Implications

The decision to classify CBD as a drug of abuse can have a significant impact on the public perception of this substance. This could lead to a misunderstanding of its actual properties and benefits, negatively influencing public opinion and potentially increasing resistance to the use of CBD even for legitimate medicinal and therapeutic applications. This shift in perception could slow down progress in medical research and therapeutic applications of CBD.

The categorization of CBD as a substance of abuse could also have significant economic consequences for the hemp industry in Italy. Businesses operating in the production and marketing of CBD products could experience disruptions in their activities, with possible financial losses due to reduced sales and potential product stigmatization. Furthermore, this decree could discourage investments in the light hemp sector, thus limiting technological innovation and market diversification related to CBD.

Many countries have embraced more progressive approaches to CBD, recognizing its benefits without considering it a substance of abuse. These international comparative analyses can provide insights into how policies could develop in a more informed and evidence-based manner, potentially influencing future regulatory decisions in Italy towards a more balanced and scientifically grounded regulation of CBD.


The postponement of the hearing highlights the attention and caution of the Regional Administrative Court of Lazio, but also underscores the immediate need for a definitive resolution based on solid scientific grounds, which could influence the future of light cannabis in Italy. This case emphasizes the importance of ongoing dialogue among legislators, scientific experts, and economic operators to develop balanced and effective policies that meet society’s needs.

The legal battle surrounding the classification of CBD is crucial not only for the hemp industry but also for public health and scientific research. The lawyers and companies involved continue to advocate for balanced regulation based on solid scientific evidence. Want to receive updates? Suscribe to our newsletter (you’ll receive a 15% discount code!) and in the meantime, try NativaCBD products! See you soon!

Leave a Reply

Your email address will not be published. Required fields are marked *

Open chat
vorrei informazioni sui vostri prodotti !